Home

Earnings Analysis

Healthcare

Summary

UniQure is upgraded from Hold to Buy, driven by near-term UK approval prospects for AMT-130 and a robust cash runway to 2029.

Despite FDA requiring a new Phase 3 trial for AMT-130 in Huntington's, a UK submission is imminent, positioning QURE for a major catalyst.

QURE’s pipeline, including AMT-260 for epilepsy and AMT-191 for Fabry, offers additional upside, though AMT-162 was discontinued.

With potential UK approval, $750m peak annual revenue by 2030 is projected, and QURE’s valuation could trend toward $3bn if milestones are met.

It will additionally be intriguing to see if high-profile departures at the FDA, plus updated four-year data from a Phase 1/2 study, soften the FDA's stance on approval.

Looking for a helping hand in the market? Members of Haggerston BioHealth get exclusive ideas and guidance to navigate any climate.…